March 29, 2019
MedPharm to develop Destiny Pharma’s formulations from XF-platform
Destiny Pharma has picked MedPharm to develop new topical formulations of its novel XF-platform compounds, new treatments for dermal and ocular infections which are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR).